Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Call us @: 844 663-3742
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|---|---|
Location Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, 91505 | Status Not Available | |
Location City Of Hope National Medical Center, Duarte, California, 91010 | Status Not Available | |
Location UCSD Moores Cancer Center, La Jolla, California, 92093-0698 | Status Not Available | |
Location University of California Los Angeles (UCLA), Los Angeles, California, 90095 | Status Not Available | |
Location Stanford University, Stanford, California, 94305 | Status Not Available | |
Location Emory University, Atlanta, Georgia, 30322 | Status Not Available | |
Location Northwestern University, Chicago, Illinois, 60611 | Status Not Available | |
Location University of Chicago, Chicago, Illinois, 60637 | Status Not Available | |
Location Norton Medical Plaza II, 3991 Dutchmans Lane, Louisville, Kentucky, 40207 | Status Not Available | |
Location Dana-Farber Cancer Institute, Boston, Massachusetts, 02215 | Status Not Available | |
Location Henry Ford Health System, Detroit, Michigan, 48202 | Status Not Available | |
Location TRIO - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169-3321 | Status Not Available | |
Location John Theurer Cancer Center, Hackensack UMC, Hackensack, New Jersey, 07601 | Status Not Available | |
Location San Juan Oncology Associates, Farmington, New Mexico, 87401 | Status Not Available | |
Location Northwell Health, New Hyde Park, New York, 11042 | Status Not Available | |
Location Memorial Sloan Kettering Cancer Center, New York, New York, 10065-6007 | Status Not Available | |
Location Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, 10065 | Status Not Available | |
Location University of Rochester, Rochester, New York, 14642 | Status Not Available | |
Location Levine Cancer Institute, Charlotte, North Carolina, 28204 | Status Not Available | |
Location Southeastern Medical Oncology Center, Goldsboro, North Carolina, 27534-9479 | Status Not Available | |
Location University of Cincinnati Medical Center, Cincinnati, Ohio, 45267 | Status Not Available | |
Location Cleveland Clinic, Cleveland, Ohio, 44195 | Status Not Available | |
Location The Ohio State University, Columbus, Ohio, 43210 | Status Not Available | |
Location Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center, Columbus, Ohio, 43219 | Status Not Available | |
Location University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104 | Status Not Available | |
Location Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232 | Status Not Available | |
Location University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009 | Status Not Available | |
Location M.D. Anderson Cancer Centre, Houston, Texas, 77030 | Status Not Available | |
Location US Oncology Research, LLC, The Woodlands, Texas, 77380 | Status Not Available | |
Location University of Vermont Medical Center, Burlington, Vermont, 05405 | Status Not Available | |
Location Swedish Cancer Institute, Seattle, Washington, 98104 | Status Not Available | |
Location Northwest Cancer Specialists, Compass Oncology, Vancouver, Washington, 09868 | Status Not Available | |
Location Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, 98801 | Status Not Available | |
Location Yakima Valley Memorial Hospital, Yakima, Washington, 98902 | Status Not Available | |
Location QEII Health Science Centre, Halifax, Nova Scotia, B3H 2Y9 | Status Not Available | |
Location Princess Margaret Cancer Centre, Toronto, Ontario, M5G2M9 | Status Not Available | |
Location McGill University Health Center, Montréal, Quebec, H4A3J1 | Status Not Available |
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
The objective of protocol PCYC-1145-LT is to provide long-term access to ibrutinib for subjects who meet the selection criteria.
Time Frame: The duration will be 3 years and will be re-evaluated.
Characterize the drug safety profile by collecting long-term safety data for ibrutinib.
Time Frame: Up to 3 years and will be re-evaluated.
Interventions:
- Drug: Ibrutinib
Enrollment:
600
Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor